BESTAGRO / Q4-FY26 / claim-ledger

Audit the questions that mattered.

Best Agrolife · Analyst questions, management answers, and the quality of the response where the ledger is available.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

NegativeQ4-FY26 · 2026-05-15Back to quarter ↗

Questions audited

Answered directly

73%

Numeric claims

Consistency

contradicted

Question ledger

What was answered, and how?

Sukrit Dartil · Eyesight Frade Private Limited

partial

Strategic levers for FY26-27 to expand portfolio, distribution, and manage risks.

We have introduced five new bio-stimulant products for FY2627. We will continue introducing new patented products. We are progressing on nano-urea registration. We are pruning non-performing dealers from our 10,800+ network. On risks, we are agile on pricing and monitoring El Nino impact.

Sukrit Dartil · Eyesight Frade Private Limited

partial

Capital allocation and risk management framework for FY26-27.

We are postponing new capex. R&D spend continues at ~1% of sales. We have filed 100+ patents. We did two rounds of price increases in April and May. We have applied for additional 20% bank funding from government scheme.

KL · Gojun Capital

direct

Percentage of sales from own manufacturing vs trading.

Almost between 60 to 65% of our sales are being produced in our own factories.

KL · Gojun Capital

partial

Capital required to replicate current manufacturing capacity.

At least 80 to 100 crores to set up a similar manufacturing facility. But technical facility built over 6-7 years with multiple expansions.

KL · Gojun Capital

direct

Margins and working capital cycle for branded vs institutional.

Branded gross margin ~40%, B2B ~15-20%. Inventory days: branded 120-150, B2B 90-120. Receivables: branded ~120 days, B2B ~90 days. EBITDA margin for branded 18-20%, B2B ~8%.

KL · Gojun Capital

direct

Concern about high receivables and potential write-offs.

Last three years doubtful debts less than 1%. We have legal cases on only ~22 crores over three years. Most receivables >6 months get collected by June-July.

KL · Gojun Capital

direct

Plans for fund raise or rights issue to strengthen balance sheet.

We have 10% unused bank facilities plus additional 20% government funding. Cash flow from operations was 90 crores despite 8 crore PAT. We are not planning a rights issue.

Wun Sharma · Individual Investor

evasive

Guidance for next financial year after repeated misses.

We are not giving any specific number on guidance. Difficult phase should be over this year. Next year should be a better number.

Sakit Kapoor · Kapoor and Company

partial

How will this year be different with more B2B technical sales?

We are diversifying from being only feeder for brand business to providing key technicals to other companies. Four new patented molecules are already in production in Q1, accelerating into Q2 and Q3.

Sakit Kapoor · Kapoor and Company

direct

Impact of deferred March sales on Q1 and sales return provisions.

Q1 will see better top line and bottom line as placements are at higher prices. Sales return as a percentage came down by 10% to ~20-21%. We aim to go below 20% next year.

Sakit Kapoor · Kapoor and Company

direct

If 50-70 cr sales were not deferred, would losses have been lower?

That 50-70 crores would have brought around 20-23 crores of profit. So loss would have been less than 15 crores.